InMed Pharmaceuticals Inc INM

Healthcare Cannabis

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

NDAQ:INM - Post by User

InMed Pharmaceuticals Inc > InMed Moving into 2021

<< Previous

Bullboard Posts

Next >>

Comment by Steveminon Dec 31, 2020 10:47am

163 Views

Post# 32203154

RE:RE:RE:InMed Moving into 2021

Bullknit, go to www.uspto.gov and set up an account (it's free) so you can search for Inmed and you'll also receive email alerts everytime there's action on an application. For some reason the link isn't working when I try to copy and paste. Below is a copy of the case info which should get you to the right spot ater you set up an account.

Status date: December 9, 2020

This table displays details of patent number 16098324.
Customer number	28381
Application number	16098324Opens in new window to Patent Application Information Retrieval.
Docket number	NMD-001/PCT/US
Patent number	Opens in new window to Patent Application Information Retrieval.
Type	UTL
Filing date	November 1, 2018
Issue date
Status	Non Final Action Mailed